In Brief This Week: Danaher; ACGT, CAP; Thermo Fisher; Quest, CDC; Cleveland Clinic Labs, ACL Labs; More | GenomeWeb

NEW YORK (GenomeWeb News) – Danaher said this week that it anticipates its second-quarter diluted net earnings per share to be "slightly above" the high end of its previously announced guidance of between $.80 and $.85. Core revenue growth, it added is expected to also be "slightly above" the previous guidance of between 1 percent and 2 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.